Our study supports the efficacy of GLP-1 RAs in reducing cardiovascular events among individuals with concurrent type 2 diabetes and AKD, highlighting their role in the complex management of these comorbid conditions. Here, GLP1R is linked to type 2 diabetes mellitus.